Ionis Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell IONS and other ETFs, options, and stocks.

About IONS

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T.

CEO

Brett P. Monia

CEOBrett P. Monia

Employees

1,402

Employees1,402

Headquarters

Carlsbad, California

HeadquartersCarlsbad, California

Founded

1989

Founded1989

Employees

1,402

Employees1,402

IONS Key Statistics

Market cap

12.52B

Market cap12.52B

Price-Earnings ratio

-35.71

Price-Earnings ratio-35.71

Dividend yield

—

Dividend yield—

Average volume

1.79M

Average volume1.79M

High today

$76.48

High today$76.48

Low today

$74.21

Low today$74.21

Open price

$74.76

Open price$74.76

Volume

2.26M

Volume2.26M

52 Week high

$86.74

52 Week high$86.74

52 Week low

$32.00

52 Week low$32.00

Stock Snapshot

Ionis Pharmaceuticals(IONS) stock is priced at $75.78, giving the company a market capitalization of 12.52B. It carries a P/E multiple of -35.71.

As of 2026-05-21, Ionis Pharmaceuticals(IONS) stock has fluctuated between $74.21 and $76.48. The current price stands at $75.78, placing the stock +2.1% above today's low and -0.9% off the high.

Ionis Pharmaceuticals(IONS) shares are trading with a volume of 2.26M, against a daily average of 1.79M.

During the past year, Ionis Pharmaceuticals(IONS) stock moved between $32.00 at its lowest and $86.74 at its peak.

IONS News

Simply Wall St 1d

Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans

Biogen and Ionis reported topline Phase 2 CELIA data for diranersen in early Alzheimer's disease, showing robust biomarker and cognitive effects. The antisense...

TipRanks 3d

Ionis Pharmaceuticals initiated with a Buy, named a top pick at Citi

Citi initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $115 price target and named it a top pick among small-to-mid cap biotech stocks. T...

Simply Wall St 5d

Assessing Ionis Pharmaceuticals Valuation As Shares Cool After A Multi Year Run

Advertisement Recent stock performance and context Ionis Pharmaceuticals (IONS) has seen its stock give back some ground recently, with the price down about 2...

Analyst ratings

88%

of 26 ratings

Buy

88.5%

Hold

11.5%

Sell

More IONS News

TipRanks 6d

Ionis Pharmaceuticals: Buy Rating Reaffirmed as Alzheimer’s Program Advances and Price Target Raised to $111 from $100

In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $111.00....

TipRanks 7d

Pelacarsen Phase 3 HORIZON Trial Seen as Key Catalyst Supporting Ionis Buy Rating and Unchanged $105 Price Target

Analyst Joseph Stringer of Needham maintained a Buy rating on Ionis Pharmaceuticals, retaining the price target of $105.00. Claim 55% Off TipRanks Unlock hedge...

People also own

Based on the portfolios of people who own IONS. This list is generated using Robinhood data, and it’s not a recommendation.

AMD

Shopify

Intel

Taiwan Semiconductor Manu…

Vertex Pharmaceuticals

Rocket Lab Corporation

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.